Introduction
Staphylococcus aureus infections remain a challenge in terms of therapeutic strategies and public health cost worldwide. MRSA strains were first described in the 1960s from nosocomial infections. 1 However, from the beginning of the 2000s, MRSA have been reported as a source of community-acquired infections (CA-MRSA), 2 primarily in skin and soft tissue infections (SSTIs). 3 S. aureus SSTIs encompass diverse clinical presentations such as folliculitis, furuncles, abscesses, paronychia, impetigo, carbuncles, cellulitis and necrotizing cellulitis. 4 These emerging CA-MRSA strains have a distinct genetic background from the traditional healthcare-associated MRSA strains, and specific lineages have emerged on different continents, including the successful USA300 clone [ST8-MRSA-IVa Panton -Valentine leucocidin (PVL)-positive] in the USA and the ST80 clone (ST80-MRSA-IV PVL-positive) in Europe. 5 -7 Regarding S. aureus CA-SSTIs, Moran et al. 5 reported a prevalence of MRSA reaching 78% in the USA 10 however, this was with heterogeneous methodologies between countries and compared with the Moran et al. 5 study. Thus, having a global picture of MRSA prevalence and clonal profile in S. aureus CA-SSTIs in Europe is highly relevant, not least because the assumed emergence of the USA300 clone in Europe may represent a threat. 6 To address these issues, we conducted a multicentre study inspired by the Moran et al. 5 study.
Patients and methods

Ethics
Written consent or non-opposition (according to each country-specific regulation) was obtained from all patients. The study was conducted in accordance with the Declaration of Helsinki. Approvals from local ethics committees were obtained for all centres. The study was registered on ClinicalTrials.gov as Identifier NCT02796742.
Patients
From 1 April to 30 June 2015, patients (adults and children) presenting to the tertiary hospital emergency department in Badalona (Spain), Brighton (UK), Bucharest (Romania), Lyon (France), Monza (Italy), Patras (Greece) and Tuebingen (Germany) with a S. aureus CA-SSTI were prospectively enrolled, based on the study criteria described by Moran et al.
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Methods
After cultures were obtained, S. aureus isolates were characterized by antimicrobial susceptibility testing, detection of PVL encoding genes and spatyping and/or MLST and/or DNA microarray according to the participating centres' facilities. Demographic, clinical information and bacteriological data were collated using a standardized form.
Results
Over the study period, 205 patients with S. aureus SSTIs were enrolled, ranging from 12 to 44 patients per participating centre. spa-type, which had been primarily described as associated with severe infections in pigs and farmers in France. 11 Regarding MRSA lineage distribution, eight different clonal complexes were described, including CC80 (n ¼ 10), CC1 (n ¼ 7), CC5 (n ¼ 6) and CC22 (n ¼ 4). Although most countries reported MRSA isolates belonging to various clonal complexes, 8 of 12 MRSA (66.7%) isolated in Greece belonged to the European ST80 clone, and in Romania all five MRSA strains belonged to the CC1 clone. Strikingly, USA300 was not detected in this study; just one isolate (from Spain) was assigned to the arginine catabolic mobile element-negative Latin variant (USA300-LV) of this clone. 12 Fifty-one isolates were PVL-positive (24.9%), with a heterogeneous distribution between countries (from 4.3% in Romania to 34.9% in France). Overall, PVL-positive strains were distributed among MSSA and MRSA, except in Greece where PVL was significantly associated with MRSA (P,0.0001), due to the predominant circulating clone ST80. MRSA antimicrobial susceptibility profiles showed that 20 isolates (58.8%) were resistant to kanamycin and 6 (17.6%) to kanamycin, tobramycin and gentamicin. Moreover, 15 MRSA were resistant to clindamycin (44.1%), 13 to fluoroquinolones (38.2%), 12 to fusidic acid (35.3%) and 3 to co-trimoxazole (8.8%).
Discussion
Inspired by the Moran et al. 5 study, which efficiently captured the CA-MRSA epidemiology in the USA 10 years ago, we aimed to determine the prevalence of MRSA in S. aureus CA-SSTIs in Europe and to assess whether the highly successful CA-MRSA USA300 clone is prevalent in such infections. We report here that MRSA accounts for 15.1% of cases, which is markedly lower than in the USA (78%). 5 Notably, we observed a wide intercountry variation ranging from 0% to 29%, with a north-to-south increasing gradient. The limitations of our study are that included centres were not exhaustive of all European countries, as for the Scandinavian countries, and that each country was represented by only one centre, although all participating centres were university hospitals serving a large population. Nevertheless, these findings are in accordance with previous studies on S. aureus infections, strengthening the validity of our methodology. 8 -10 The circulating clones, whatever their methicillin resistance or PVL status, appeared to be genetically diverse and with no predominant lineage, except for the ST80 clone in Greece, as already described. 7 Interestingly, 4.4% (9 of 205) of strains (isolated in France, UK and Italy) belonged to the S. aureus CC398 emerging lineage. Most importantly, the CA-MRSA USA300 clone was not detected in our cohort, suggesting that the success of this CA clone in the USA is not superimposable in Europe, despite some published data reporting its emergence in the continent, 13 and confirming the predicted global decline of this clone.
14 There are currently no convincing explanations for the lack of epidemiological success of the CA-MRSA USA300 lineage in Europe. However, one could speculate on the effects of cultural and social differences, living conditions, dietary habits and professional mobility.
To the best of our knowledge, this is the first multicentre study investigating the prevalence and characteristics of MRSA in S. aureus CA-SSTIs in Europe. Our study reveals the specificity of the European CA-MRSA epidemiology compared with the US,
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MRSA in CA-SSTIs in Europe JAC and tempers the potential threat of USA300 clone in such infections in the European continent. However, given the current major migratory flow from the Middle East and Africa, the European epidemiology of S. aureus infections may be modified noticeably in the near future.
As a conclusion, we can only strongly advocate the characterization of S. aureus isolates by molecular typing in case of severe or recurrent SSTIs, cluster of cases and outbreaks, to monitor any emerging phenomenon and to decolonize patients with such PVL-positive MSSA and MRSA infections.
